Edit
Accuri Cytometers
http://www.accuricytometers.com/Last activity: 17.07.2021
Active - Reference to BD Accuri
Now a wholly owned subsidiary of BD, Accuri Cytometers, Inc. was founded to address a compelling need: life scientists love the rapid cell-by-cell analysis capability of flow cytometers, but too few have a flow cytometer in their lab. The barriers for most researchers include cost of the instrument, complexity of the software, effort required for maintenance, and the large amount of bench space required for the instrument.
With a tight focus on creating an affordable, robust, easy-to-use flow cytometer, our engineering team went back to basic principles and designed an innovative instrument from the ground up to meet our customer-driven specifications.
With a tight focus on creating an affordable, robust, easy-to-use flow cytometer, our engineering team went back to basic principles and designed an innovative instrument from the ground up to meet our customer-driven specifications.
Location: United States, Michigan, Ann Arbor
Employees: 51-200
Total raised: $10M
Founded date: 2004
Investors 1
| Date | Name | Website |
| 17.07.2021 | Baird Capi... | bairdcapit... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 12.07.2010 | Series E | $6M | - |
| 13.07.2009 | - | $4M | - |
Mentions in press and media 9
| Date | Title | Description |
| 15.06.2012 | Augment Ventures’ Vijayargiya Feels Bullish About Midwestern Cleantech | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Sonali Vijayargiya is back in Michigan after representing Midwestern VCs in the U.S. Department of Energy’s (DOE) National Clean Energy Business Plan Competition, which was he... |
| 11.01.2012 | Flagship Ventures $270M fund gives early stage investing a shot in the arm | This is the largest fund the VC firm has raised, coming on the heels of a $235 million fund raised in 2007. And the closing of Flagship Venture Fund IV brings the total amount of early stage capital under management to $900 million. The com... |
| 13.09.2011 | New closed-system IV medical device could be on the market by 2012 | A Michigan company expects its new intravenous delivery system to be on the market next year after securing a fresh round of capital. Tangent Medical Technologies has developed a closed-system IV device, NovaCath, that will stay comfortably... |
| 12.07.2010 | Accuri Cytometers, a Baird Venture Partners Portfolio Company, Completes $6 Million Series E Financing | - |
| 12.07.2010 | Accuri Cytometers Completes $6M Series E Financing | Accuri Cytometers, Inc., an Ann Arbor, MI-based developer and provider of flow cytometers to life science researchers, completed a $6m Series E preferred stock financing. The round included existing investors Arboretum Ventures, Baird Ventu... |
| 13.07.2009 | Michigan’s Accuri Cytometers raises $4 million | Promoted Covid-19’s terrible toll on diabetes patients. What can be done? The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| - | Flagship Ventures $270M fund gives early stage investing a shot in the arm | Early stage investing and medical technology innovation just got a boost, which is welcome news to healthcare entrepreneurs. Flagship Ventures, a Cambridge, Massachusetts venture capital company aimed at healthcare and green companies, anno... |
| - | Michigan’s Accuri Cytometers raises $4 million | ANN ARBOR, Michigan — Accuri Cytometers, which makes low-cost bench-top cell analysis products, has raised $4 million to expand its manufacturing and customer service capabilities. The company said it needed the money to keep up with demand... |
| - | New closed-system IV medical device could be on the market by 2012 | A Michigan company expects its new intravenous delivery system to be on the market next year after securing a fresh round of capital. Tangent Medical Technologies has developed a closed-system IV device, NovaCath, that will stay comfortably... |